Latest Breaking News On - ஆழமான நிஷார் - Page 4 : comparemela.com
UPDATE 1-3D printer Formlabs doubles valuation after SoftBank fund-led investment round
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
SambaNova raises $676M at a $5 1B valuation to double down on cloud-based AI software for enterprises – TechCrunch
techcrunch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from techcrunch.com Daily Mail and Mail on Sunday newspapers.
2 Min Read
(Reuters) - ElevateBio said on Monday it has raised $525 million in new funding led by Matrix Capital Management, to help increase manufacturing capacity and also advance development of its cell and gene therapies.
The new financing, one of the bigger fund raises in the healthcare sector this year, also included investment from SoftBank Vision Fund 2, the cell and gene therapy developer said.
The company is the largest shareholder in cell therapy developer Allovir Inc, and its other portfolio companies include HighPassBio, which is also developing a treatment for leukemia patients.
ElevateBio is seeing demand for manufacturing services from both its portfolio companies, as well as from academic researchers and biotech companies, said co-founder and Chief Executive Officer David Hallal.
Cell and Gene Therapy Portfolio Builder ElevateBio Raises $525M in Financing
Cell and gene therapy company ElevateBio has completed a $525 million Series C financing, with plans to use the proceeds toward developing and expanding its technology platforms, growing its network of process development and GMP manufacturing capacity, advancing industry partnerships, and continuing to develop candidates through its portfolio of companies. [ElevateBio]
March 15, 2021
Cell and gene therapy company ElevateBio has completed a $525 million Series C financing, with plans to use the proceeds toward developing and expanding its technology platforms, growing its network of process development and GMP manufacturing capacity, advancing industry partnerships, and continuing to develop candidates through its portfolio of companies. [ElevateBio]